Although grade 2 neutropenia occurred in 20 (35.7%) patients, all were successfully managed with filgrastim (granulocyte-macrophage colony-stimulating factor (GM-CSF)) administered every third day during the first two treatment cycles, allowing all patients to complete the full course of therapy. Here, CSF2 is linked to neutropenia.